The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Peripheral neuropathy and antiretroviral drugs
Abstract
Abstract Patients treated with nucleoside analogue reverse transcriptase inhibitors (NRTIs) develop a varying degree of myopathy or neuropathy after long‐term therapy. Zidovudine (AZT) causes myopathy; zalcitabine (ddC), didanosine (ddI) and lamuvidine (3TC) cause neuropathy; stavudine (d4T) and fialuridine (FIAU) cause neuropathy or myopathy and lactic acidosis. The tissue distribution of phosphorylases responsible for phosphorylation of NRTIs relates to their selective tissue toxicity. The myopathy is characterized by muscle wasting, myalgia, fatigue, weakness and elevation of CK. The neuropathy is painful, sensory and axonal. In vitro, NRTIs inhibit the gamma‐DNA polymerase, responsible for replication of mtDNA, and cause mtDNA dysfunction. In vivo, patients treated with AZT, the best studied NRTI, develop a mitochondrial myopathy with mtDNA depletion, deficiency of COX (complex IV), intracellular fat accumulation, high lactate production and marked phosphocreatine depletion, as determined with in vivo MRS spectroscopy, due to impaired oxidative phosphorylation. Animals or cultured cells treated with NRTIs develop neuropathy, myopathy, or cell destruction with similar changes in the mitochondria. There is evidence that the NRTI‐related neuropathy is also due to mitochondrial toxicity. The NRTIs (AZT, ddC, ddI, d4T, 3TC) contain azido groups that compete with natural thymidine triphosphate as substrates of DNA pol‐gamma and terminate mtDNA synthesis. In contrast, FIAU that contains 3′‐OH groups serves as an alternate substrate for thymidine triphosphate with DNA pol‐gamma and is incorporated into the DNA causing permanent mtDNA dysfunction. The NRTI‐induced mitochondrial dysfunction has an influence on the clinical application of these agents, especially at high doses and when combined. They have produced in humans a new category of acquired mitochondrial toxins that cause clinical manifestations resembling the genetic mitochondrial disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration
Richardson, F. C., Engelhardt, J. A., & Bowsher, R. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12003 · Cited by 58
Cited by
Animal models of neuropathic pain
Jaggi, A. S., Jain, V., & Singh, N. (2011) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00801.x · Cited by 387
A modern approach to the treatment of mitochondrial disease
The Mitochondrial Medicine Society, Parikh, S., Saneto, R., Falk, M. J., Anselm, I., Cohen, B. H., & Haas, R. (2009) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0046-0 · Cited by 348
A Review of the Toxicity of HIV Medications
Margolis, A. M., Heverling, H., Pham, P. A., & Stolbach, A. (2014) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0325-8 · Cited by 348
Access to pain treatment as a human right
Lohman, D., Schleifer, R., & Amon, J. J. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-8 · Cited by 321
SIAU, C., XIAO, W., & BENNETT, G. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.05.007 · Cited by 300
Metadata
- Authors
- Dalakas, M. C.
- Venue
- Journal of the Peripheral Nervous System
- Publisher
- Wiley
- Published
- 2001-03
- Volume
- 6
- Issue
- 1
- Pages
- 14-20
- ISSN
- 1085-9489 (ISSN-L)
- 1529-8027
- OpenAlex
- W2044839807
- Cited by
- 224
- References
- 1
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peripheral neuropathy and antiretroviral drugs. https://app.cochat.ai/papers/10.1046/j.1529-8027.2001.006001014.x
- The paper
- Dalakas, M. C. (2001). Peripheral neuropathy and antiretroviral drugs. Journal of the Peripheral Nervous System. https://doi.org/10.1046/j.1529-8027.2001.006001014.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.